Clinical Trial Update: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial investigating RC48-ADC given IV in HER2-positive metastatic breast cancer, with or without liver metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Liver Metastases

Drugs mentioned

• RC48-ADC (Disitamab Vedotin)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Breast Neoplasms, Breast Diseases | Phase 2, Phase 3 | Status: UNKNOWN